Yazar "Demir, M." seçeneğine göre listele
Listeleniyor 1 - 20 / 47
Sayfa Başına Sonuç
Sıralama seçenekleri
Öğe Acquired hemophilia A and the knowledge/awareness level of Turkish hematology fellows: On behalf of the Turkish Hematology Association, Acquired Hemophilia Working Group(Wiley-Blackwell, 2012) Demir, M.; Unuvar, A.; Aksu, S.; Antmen, B.; Ar, C.; Baslar, Z.; Gursel, T.[Abstract Not Available]Öğe Assessment of thrombin formation in patients with ulcerative colitis without a history of thrombotic events(Wiley-Blackwell, 2013) Demir, M.; Halhalli, S.; Tezel, A.; Ustundag, A.; Can, G.; Umit, E.[Abstract Not Available]Öğe Asymmetric dimethylarginine and nitric oxide levels in migraine during interictal period(Wiley-Blackwell, 2008) Guldiken, B.; Demir, M.; Guldiken, S.; Turgut, N.; Ozkan, H.; Kabayel, L.; Tugrul, A.[Abstract Not Available]Öğe Asymmetric dimethylarginine and nitric oxide levels in migraine during the interictal period(Elsevier Sci Ltd, 2009) Guldiken, B.; Demir, M.; Guldiken, S.; Turgut, N.; Ozkan, H.; Kabayel, L.; Tugrul, A.Nitric oxide (NO), which modulates endothelial function, is thought to be pivotal in the pathophysiology of migraines. The connection between migraine and cardiovascular diseases has also drawn attention to the endothelial dysfunctions and NO pathway abnormalities seen in patients with migraine. Our goal was to assess the levels of NO and the endogenous NO synthase inhibitor, asymmetric dimethylarginine (ADMA), in people with migraine during the interictal period. A total of 49 patients with migraine and 22 control subjects were enrolled in the study. Their plasma NO metabolites (nitrite [NO2-] and nitrate [NO3-]) and ADMA levels were measured using the enzyme-linked immunosorbent assay method, and were then compared with their cardiovascular risk factors, anthropometric measurements, and headache frequency and severity. The plasma ADMA, NO2 and NO3 levels of the patients with migraine during the interictal period did not differ from the control group, and no relationship was found between cardiovascular risk factors and migraine attack severity and frequency. We conclude that, in patients with migraine, there is no dysfunction of baseline NO and ADMA metabolism during the interictal period. (C) 2008 Elsevier Ltd. All rights reserved.Öğe ATHEROSCLEROSIS AND RELATED FACTORS IN PATIENTS WITH PHILADELPHIA-NEGATIVE CHRONIC MYELOPROLIFERATIVE NEOPLASMS(Ferrata Storti Foundation, 2015) Demir, M.; Umit, E.; Uyanik, S.; Ermis, V.; Tuncel, S.; Pamuk, G.[Abstract Not Available]Öğe Chaining trends in anti-coagulant therapies. Are heparins and oral anti-coagulants challenged?(Edizioni Minerva Medica, 2008) Fareed, J.; Iqbal, O.; Cunanan, J.; Demir, M.; Wahi, R.; Clarke, A.; Adiguzel, C.The conventional management of thrombotic and cardiovascular disorders is based on the use of heparin, oral anticoagulants and aspirin. Despite progress in the sciences, these drugs still remain a challenge and mystery. The development of low molecular weight heparins (LMWHS) and the synthesis of heparinomimetics represent a refined use of heparin. Additional drugs will continue to develop. However, none of these drugs will ever match the polypharmacology of heparin. Aspirin still remains the leading drug in the management of thrombotic and cardiovascular disorders. The newer antiplatelet drugs such as adenosine diphosphate receptor inhibitors, GPIIb/IIIa inhibitors and other specific inhibitors have limited effects and have been tested in patients who have already been treated with aspirin. Warfarin provides a convenient and affordable approach in the long-term outpatient management of thrombotic disorders. The optimized use of these drugs still remains the approach of choice to manage thrombotic disorders. The new anticoagulant targets, such as tissue factor, individual clotting factors, recombinant forms of serpins (antithrombin, heparin co-factor II and tissue factor pathway inhibitors), recombinant activated protein C, thrombomodulin and site specific serine proteases inhibitors complexes have also been developed. There is a major thrust on the development of orally bioavailable anti-Xa and IIa agents, which are stated to replace oral anticoagulants. Both the anti-factor Xa and anti-IIa agents have been developed for oral use and have provided impressive clinical results. However, safety concerns related to liver enzyme elevations and thrombosis rebound have been reported with their use. For these reasons, the US Food and Drug Administration did not approve the orally active antithrombin agent Ximelagatran for several indications. The synthetic pentasaccharide (Fondaparinux) has undergone clinical development. Unexpectedly, Fondaparinux also produced major bleeding problems at minimal dosages. Fondaparinux represents only one of the multiple pharmacologic effects of heparins. Thus, its therapeutic index will be proportionately narrower. The newer antiplatelet drugs have added a new dimension in the management of thrombotic disorders. The favorable clinical outcomes with aspirin and clopidogrel have validated COX-I and P2Y(12) receptors as targets for new drug development. Prasugrel, a novel thienopyridine, Cangrelor and AZD 6140 represent newer P2Y12 antagonists. Cangrelor and AZD 6140 are direct inhibitors, whereas Prasugrel requires metabolic activation. While clinically effective, recent results have prompted a closure of a clinical trial with Prasugrel due to bleeding. The newer anticoagulant and antiplatelet drugs are attractive, however, none of these are expected to replace the conventional drugs in polytherapeutic approaches. Heparins, warfarin and aspirin will continue to play a major role in the management of thrombotic and cardiovascular disorders for years to come.Öğe THE CLINICAL FEATURES OF 105 CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS FOLLOWED UP AT A SINGLE CENTER IN TURKEY(Ferrata Storti Foundation, 2012) Pamuk, G.; Uyanik, M.; Akker, M.; Demir, M.[Abstract Not Available]Öğe CLINICAL FEATURES OF MYELODYSPLASTIC SYNDROME PATIENTS IN ONE CENTER IN NORTHWESTERN TURKEY(Pergamon-Elsevier Science Ltd, 2015) Pamuk, G.; Uyanik, M.; Maden, M.; Puyan, F. Oz; Demir, M.[Abstract Not Available]Öğe COMPARISON OF BONE MARROW INVOLVEMENT BY FDG PET/CT AND HISTOPATHOLOGY IN PATIENTS WITH LYMPHOMA(Ferrata Storti Foundation, 2013) Umit, E.; Serim, B.; Altun, G.; Puyan, F.; Pamuk, G.; Demir, M.[Abstract Not Available]Öğe Comparison of risk factors for warfarin-associated bleeding(Wiley-Blackwell, 2015) Ozgenel, M.; Umit, E.; Turan, N.; Demir, M.[Abstract Not Available]Öğe THE COMPARISON OF THE PROGNOSIS SCORING SYSTEMS BETWEEN EVENT-FREE SURVIVAL AT FIRST 24 MONTHS AND OVERALL SURVIVAL IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA(Ferrata Storti Foundation, 2016) Maden, M.; Demir, M.; Gokyer, A.; Bas, V.; Kubuc, K. Sacar[Abstract Not Available]Öğe COST ANALYSIS OF VENOUS THROMBOEMBOLISM PROPHYLAXIS AFTER TOTAL KNEE REPLACEMENT AND TOTAL HIP REPLACEMENT(Elsevier Science Inc, 2012) Marmarali, B.; Altintas, F.; Bal, K.; Bozkurt, K.; Demir, M.; Erdemli, B.; Ince, B.[Abstract Not Available]Öğe THE COST-EFFECTIVENESS OF RIVAROXABAN COMPARED TO ENOXAPARIN PLUS ADJUSTED-DOSE WARFARIN FOR THE TREATMENT OF DEEP VENOUS THROMBOSIS (DVT) IN TURKEY(Elsevier Science Inc, 2013) Parali, E.; Ozdemir, O.; Bozkurt, K.; Demir, M.; Ince, B.; Kultursay, H.; Ongen, G.[Abstract Not Available]Öğe THE COST-EFFECTIVENESS OF RIVAROXABAN FOR THE PREVENTION OF STROKE IN PATIENTS WITH ATRIAL FIBRILLATION (AF) IN TURKEY(Elsevier Science Inc, 2013) Marmarali, B.; Ozdemir, O.; Bozkurt, K.; Demir, M.; Ince, B.; Kultursay, H.; Ongen, G.[Abstract Not Available]Öğe THE COST-OF-DISEASE OF DEEP VENOUS THROMBOSIS AND ITS SHORT- AND LONG-TERM CLINICAL CONSEQUENCES IN TURKEY: AN EXPERT PANEL APPROACH FOR ESTIMATION OF COSTS(Elsevier Science Inc, 2013) Deger, C.; Ozdemir, O.; Bozkurt, K.; Demir, M.; Ince, B.; Kultursay, H.; Ongen, G.[Abstract Not Available]Öğe THE COST-OF-DISEASE OF THROMBOEMBOLIC AND HEMORRHAGIC COMPLICATIONS ASSOCIATED WITH ATRIAL FIBRILLATION AND ITS TREATMENT IN TURKEY: AN EXPERT PANEL APPROACH FOR ESTIMATION OF COSTS(Elsevier Science Inc, 2013) Deger, C.; Ozdemir, O.; Bozkurt, K.; Demir, M.; Ince, B.; Kultursay, H.; Ongen, G.[Abstract Not Available]Öğe COULD CHROMOSOMAL MOSAICISM PREDICT OVERALL SURVIVAL IN MYELODYSPLASTIC SYNDROMES?(Pergamon-Elsevier Science Ltd, 2015) Pamuk, G.; Uyanik, M.; Maden, M.; Gurkan, H.; Demir, M.[Abstract Not Available]Öğe COX-2 EXPRESSION AND MICROVESSEL DENSITY IN DIFFUSE LARGE B CELL LYMPHOMA(Ferrata Storti Foundation, 2010) Ozturk, E.; Puyan, F. Oz; Tekgunduz, E.; Demir, M.[Abstract Not Available]Öğe DOES ANTI-TNF THERAPY CAUSE ANY CHANGE IN PLATELET ACTIVATION IN ANKYLOSING SPONDYLITIS PATIENTS?(Ferrata Storti Foundation, 2009) Pamuk, G. E.; Pamuk, Oe N.; Orum, H.; Turgut, B.; Demir, M.[Abstract Not Available]Öğe The effect of the ratio between angiogenic and antiangiogenic factors on patients' survival in advanced nonsmall cell lung cancer(Elsevier Science Inc, 2009) Demir, V; Demir, M.; Cicin, I; Pamuk, G. E.; Ozturk, E.; Tekgunduz, E.; Caglar, T.[Abstract Not Available]
- «
- 1 (current)
- 2
- 3
- »
